Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Association of anti-topoisomerase I with cancer.

Literature DB >> 1318051

Association of anti-topoisomerase I with cancer.

N Rothfield, S Kurtzman, D Vazques-Abad, C Charron, L Daniels, B Greenberg.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1992 PMID： 1318051 DOI： 10.1002/art.1780350621

Source DB: PubMed Journal: Arthritis Rheum ISSN： 0004-3591

Keyword Cloud
Cited

× No keyword cloud information.

9 in total

1. Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival.

Authors: Abdulla Watad; Dennis McGonagle; Nicola L Bragazzi; Shmuel Tiosano; Doron Comaneshter; Yehuda Shoenfeld; Arnon D Cohen; Howard Amital
Journal: Oncoimmunology Date: 2019-03-24 Impact factor: 8.110

2. IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors: Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal: J Clin Lab Anal Date: 2009 Impact factor: 2.352

Review 3. Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors: C G Kallenberg
Journal: Clin Rev Allergy Date: 1994

Review 4. Systemic Sclerosis Association with Malignancy.

Authors: Gemma Lepri; Martina Catalano; Silvia Bellando-Randone; Serena Pillozzi; Elisa Giommoni; Roberta Giorgione; Cristina Botteri; Marco Matucci-Cerinic; Lorenzo Antonuzzo; Serena Guiducci
Journal: Clin Rev Allergy Immunol Date: 2022-09-19 Impact factor: 10.817

Review 5. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors: Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal: Wien Med Wochenschr Date: 2008

6. Risk factors for malignancy in systemic sclerosis patients.

Authors: T Kaşifoğlu; Ş Yaşar Bilge; F Yıldız; G Özen; Y Pehlivan; N Yılmaz; F Tarhan; S Yılmaz; A Küçük; H Emmungil; S S Koca; M Çınar; H Direskeneli; E Erken; G Can; M Özmen; E Gönüllü; B Kisacik; K Aksu; O Karadağ; N Kasifoglu; D Arslantas; F Sahin; G Keser; S Yavuz; M Birlik; A M Onat
Journal: Clin Rheumatol Date: 2016-04-27 Impact factor: 2.980